Essential thrombocythaemia treated with recombinant interferon: 'real world' United Kingdom referral centre experience.
In: British Journal of Haematology, Jg. 186 (2019-08-15), Heft 4, S. 561-564
academicJournal
Zugriff:
Summary: Standard first‐line therapy choice for essential thrombocythaemia (ET) requiring cytoreduction, supported by randomized trials, is low‐dose aspirin with hydroxycarbamide, but the role of recombinant interferon‐alfa (IFNα)‐2a/2b and pegylated (PEG)‐IFN‐α‐2a/2b is increasingly highlighted. Longer‐term outcome data, however, remains somewhat scarce, particularly in the 'real world'. We hereby report on a large, well‐annotated cohort of ET patients from a single referral centre undergoing therapy with either IFNα or (PEG)‐IFN‐α‐2a/2b and demonstrate high rates of complete haematological responses, good tolerability and safety, low rates of thromboembolic events in compliant patients and confirm feasibility of long‐term therapy in a significant proportion of patients. [ABSTRACT FROM AUTHOR]
Titel: |
Essential thrombocythaemia treated with recombinant interferon: 'real world' United Kingdom referral centre experience.
|
---|---|
Autor/in / Beteiligte Person: | Desterro, Joana ; McLornan, Donal P. ; Curto Garcia, Natalia ; O'Sullivan, Jennifer ; Alimam, Samah ; Keohane, Clodagh ; Woodley, Claire ; Francis, Yvonne ; Kordasti, Shahram ; Radia, Deepti H. ; Harrison, Claire N. |
Zeitschrift: | British Journal of Haematology, Jg. 186 (2019-08-15), Heft 4, S. 561-564 |
Veröffentlichung: | 2019 |
Medientyp: | academicJournal |
ISSN: | 0007-1048 (print) |
DOI: | 10.1111/bjh.15968 |
Schlagwort: |
|
Sonstiges: |
|